{
    "Clinical Trial ID": "NCT00475085",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm II",
        "  Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.",
        "  placebo : Given orally",
        "  prochlorperazine : Given orally or IV",
        "  granisetron hydrochloride : Given orally or IV",
        "  dexamethasone : Given orally or IV",
        "INTERVENTION 2: ",
        "  Arm III",
        "  Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.",
        "  placebo : Given orally",
        "  aprepitant : Given orally or IV",
        "  palonosetron hydrochloride : Given orally or IV",
        "  dexamethasone : Given orally or IV"
    ],
    "Eligibility": [
        "Inclusion criteria:",
        "  Have a diagnosis of cancer and be chemotherapy naive.",
        "  Must be scheduled to receive a chemotherapy treatment containing doxorubicin hydrochloride, epirubicin hydrochloride, cisplatin, carboplatin, or oxaliplatin (any dose or schedule) without concurrent radiotherapy or interferon treatment",
        "  Chemotherapy may be for adjuvant, neoadjuvant, curative or palliative intent.",
        "  Dose-dense regimens (e.g. chemotherapy with doxorubicin or epirubicin given every two weeks)are allowed.",
        "  For the purposes of this study, Day 1 of chemotherapy will be defined as the day of administration of cisplatin, carboplatin, oxaliplatin, doxorubicin or epirubicin.",
        "  Regimens with multiple-day doses of doxorubicin, epirubicin, cisplatin, carboplatin, oxaliplatin, dacarbazine, hexamethylmelamine, nitrosoureas, or streptozocin are not allowed. Chemotherapy agents, other than those listed above, may be given orally, intravenously, or by continuous infusion on one or multiple days.",
        "  Able to understand English",
        "Exclusion criteria:",
        "  No symptomatic brain metastases",
        "  No concurrent or impending bowel obstruction",
        "  Regimens containing liposomal doxorubicin or cisplatin are not allowed.",
        "  No concurrent pimozide, terfenadine, astemizole, or cisapride",
        "  No concurrent doxorubicin hydrochloride liposome or cisplatin",
        "  No concurrent multiple-day doses of dacarbazine, altretamine, nitrosoureas, streptozocin, cisplatin, carboplatin, or oxaliplatin"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Home Record: Severity of Delayed Nausea",
        "  1=not at all nauseated to 7=extremely nauseated, therefore higher values are worse",
        "  Time frame: average of day 1 afternoon, evening and night, and all of days 2 and 3",
        "Results 1: ",
        "  Arm/Group Title: Arm II",
        "  Arm/Group Description: Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.",
        "  placebo : Given orally",
        "  prochlorperazine : Given orally or IV",
        "  granisetron hydrochloride : Given orally or IV",
        "  dexamethasone : Given orally or IV",
        "  Overall Number of Participants Analyzed: 234",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  1.88         (1.27)",
        "Results 2: ",
        "  Arm/Group Title: Arm III",
        "  Arm/Group Description: Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.",
        "  placebo : Given orally",
        "  aprepitant : Given orally or IV",
        "  palonosetron hydrochloride : Given orally or IV",
        "  dexamethasone : Given orally or IV",
        "  Overall Number of Participants Analyzed: 241",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  1.65         (1.15)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6",
        "  Lymphoma *1/254 (0.39%)",
        "  Neutropenia *0/254 (0.00%)",
        "  Pancytopenia *0/254 (0.00%)",
        "  Trombocytopenia *0/254 (0.00%)",
        "  Gastrointestinal *1/254 (0.39%)",
        "  GI Bleed *0/254 (0.00%)",
        "  Nausea/Vomiting *1/254 (0.39%)",
        "  Chest Pain *0/254 (0.00%)",
        "  Dehydration *0/254 (0.00%)",
        "  Edema *0/254 (0.00%)",
        "  Fatigue *0/254 (0.00%)",
        "  Headache *1/254 (0.39%)",
        "  Migraine *0/254 (0.00%)",
        "Adverse Events 2:",
        "  Total: 17",
        "  Lymphoma *0/260 (0.00%)",
        "  Neutropenia *3/260 (1.15%)",
        "  Pancytopenia *1/260 (0.38%)",
        "  Trombocytopenia *0/260 (0.00%)",
        "  Gastrointestinal *3/260 (1.15%)",
        "  GI Bleed *0/260 (0.00%)",
        "  Nausea/Vomiting *1/260 (0.38%)",
        "  Chest Pain *1/260 (0.38%)",
        "  Dehydration *1/260 (0.38%)",
        "  Edema *1/260 (0.38%)",
        "  Fatigue *1/260 (0.38%)",
        "  Headache *0/260 (0.00%)",
        "  Migraine *0/260 (0.00%)"
    ]
}